Compare iShares International Treasury Bond ETF (IGOV) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares International Treasury Bond ETF vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? iShares International Treasury Bond ETF trades at $39.67 (market cap $1.31B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $977.37M). The key difference: iShares International Treasury Bond ETF is the larger of the two by market cap, and Maravai LifeSciences Holdings Inc. Class A Common Stock is trading nearer its 52-week high, iShares International Treasury Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares International Treasury Bond ETF for 92 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| IGOV | MRVI | |
|---|---|---|
Market Cap | $1.31B | $977.37M |
Volume | 69,817 | 2,742,564 |
Sector | Fixed Income | Health |
52-Week High | $42.99 | $9.00 |
52-Week Low | $39.58 | $2.83 |
Typical Hold Time | 92 Days | 0 Days |
Enterprise Value | — | $1.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IGOV trades at $39.79, up 0.53% with mixed technical signals showing bearish moving averages but bullish oscillators. The stock faces resistance at $40-$42 while finding support near $39. Financial ratios remain unavailable, requiring deeper fundamental analysis to assess valuation and profitability metrics.
The stock's outlook remains uncertain with technical indicators conflicting and limited fundamental data available. Rising bond yields create macroeconomic headwinds for equities, though inverse Treasury ETF opportunities mentioned in recent news could signal defensive positioning. Investors need updated financial disclosures to properly evaluate investment merit.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares International Treasury Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index and will invest at least 90% of its assets in fixed income securities included in the underlying index. The underlying index measures the performance of fixed-rate, local currency, investment-grade, sovereign bonds from certain developed markets. The fund is non-diversified.
Read more on IGOV →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
